

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/005223 A1

(51) International Patent Classification⁷:
C08G 61/08, B01J 31/24, C07F 15/00

C07C 6/04,

(74) Agent: LE ROUX, Mario; D M KISCH INC., P. O. BOX 781218, Sandton, 2146 (ZA).

(21) International Application Number:
PCT/ZA2003/000087

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 4 July 2003 (04.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002/5387 5 July 2002 (05.07.2002) ZA

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): SASOL TECHNOLOGY (PTY) LIMITED [ZA/ZA]; 1 Sturdee Avenue, Rosebank, Johannesburg, 2196 (ZA).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2004/005223 A1

(54) Title: PHOSPHORUS CONTAINING LIGANDS FOR METATHESIS CATALYSTS

(57) Abstract: The use of a phosphorus containing Ligand as a Ligand for a metathesis catalyst in a catalysed metathesis reaction wherein the phosphorus containing Ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound. The invention also relates to a metathesis catalyst such a phosphorus containing Ligand and to a metathesis reaction using the catalyst.

Technical Field


The invention relates to the use of a phosphorus containing ligand in the preparation of a metathesis catalyst and to the use of a phosphorus containing ligand in a catalysed metathesis reaction. The invention also relates to a metathesis catalyst including such a phosphorus containing ligand and to a metathesis reaction using the catalyst.

Background to the invention

10

There is considerable interest regarding the formation of carbon-carbon bonds via olefin metathesis. Olefin metathesis (or disproportionation) refers to the metal-catalysed redistribution of carbon-carbon double bonds. Cross metathesis (CM) can be described as a metathesis reaction between two non-cyclic olefins,

15 which may be the same or different, for example:



Where the olefins are the same, the reaction is known as self metathesis.


20 Ring-opening metathesis polymerization (ROMP) is a variant of olefin metathesis reactions wherein cyclic olefins (for example) produce polymers and copolymers, for example:

2



Ring-closing metathesis (RCM) represents a process in which an acyclic diene (for example) is cyclised to produce a cycloalkene, for example;

5




As indicated above metathesis reactions take place in the presence of a catalyst.

A great deal of research has been done in an attempt to synthesise and isolate catalysts which are able to catalyse homogeneous olefin metathesis reactions.

10 More particularly the synthesis of Group VIII transition metal metathesis catalysts has lead to catalysts with increased functional group tolerance and stability with respect to conditions such as air, water and acids.

During the 1990's the so-called "1st generation Grubbs catalyst" of formula 1a
15 was developed:



.....(1a)


20 where Cy is cyclohexyl.

This well defined ruthenium (Ru) alkylidene catalyst afforded high selectivities, high reaction rates and good tolerance for oxygenates in feed during homogeneous olefin metathesis reactions, including cross metathesis, ring closing metathesis and ring opening metathesis polymerisation. These processes
5 have many potential commercial applications for the commodities, pharmaceutical and fine chemicals industries as well as in the field of speciality polymers. Several reviews describe the development and applications of Grubbs-type catalysts (for example Acc. Chem. Res. 2001, 34, 18-24; Angew. Chem., Int .Ed., 2000, 39, 3012-3043).

10

Much research has been carried out to investigate the effect of changing the nature of the ligands, (for example J. Am. Chem. Soc. 1997, 119, 3887 – 3897; Tetrahedron Lett. 1999, 40, 2247-2250; Angew. Chem., Int. Ed. 1998, 37, 2490-2493) resulting in the development of second generation Grubbs catalysts. The
15 main thrust of second generation Grubbs catalyst research has related to a move away from the use of phosphine ligands to the use of highly nucleophilic N-heterocyclic carbenes for homogeneous metathesis reactions. Formula 1b shows the structure of the standard second generation Grubbs catalyst. While this catalyst shows greater reactivity compared to catalyst 1a, it is more expensive
20 than the first generation catalyst.

4




where Cy = cyclohexyl and Mes = mesityl

.....(1b)

5

In the case of hydroformylation reactions, research has continued into the use of phosphine ligands. It will be appreciated that in a hydroformylation process an olefinic feedstock is reacted with carbon monoxide and hydrogen at elevated temperatures and pressures in the presence of a hydroformylation catalyst to produce oxygenated products. The hydroformylation catalyst is selected according to the particular oxygenated products which are required from a particular olefinic feedstock and may typically be phosphine and/or phosphite ligand modified rhodium (Rh) or cobalt (Co) catalyst. Many different phosphine and phosphite ligands have been suggested in the past. For example US 3,400,163 discloses bicyclic heterocyclic sec-and tert-phosphines of the general formula 1c and it is stated that these phosphines are useful in the hydroformylation of olefins.



US 3,420,898 discloses olefin hydroformylation reactions in the presence of a cobalt catalysts with phosphine ligand of formula 1c.

5 Research has indicated that those phosphine ligands which appeared to lead to catalysts with higher selectivities and reaction rates in homogeneous metathesis reactions were often not suitable for the types of catalysts used in hydroformylation reactions, for example HCo(CO)₃P where P represents a phosphine ligand, for example tricyclohexyl phosphine (PCy₃).

10

However, it has now surprisingly been found that certain relatively inexpensive (compared to second generation Grubbs catalysts) phosphorus containing ligands such as phosphabicylononane ligands, which have been used in hydroformylation reactions, provide excellent stability, product yields and 15 selectivities when used in a homogeneous metathesis catalyst. In addition, it has surprisingly been found that metathesis catalysts incorporating these phosphorus containing ligands in at least some cases show enhanced resistance to feed impurities. Furthermore, in at least some cases these catalysts afford superior performance for ring closing metathesis, ring opening metathesis polymerization 20 and cross metathesis when compared to the standard first generation Grubbs catalyst (1a). When compared to the rather expensive standard second generation Grubbs catalyst (1b), in at least some cases their activity is comparable while the reaction selectivity is often superior.

Summary of the invention

According to a first aspect of the present invention there is provided the use of a phosphorus containing ligand as a ligand for a metathesis catalyst in a catalysed

5 metathesis reaction wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound.

According to a second aspect of the present invention there is provided the use

10 of a phosphorus containing ligand in the preparation of a catalyst containing the ligand, which catalyst is for use in a metathesis reaction, wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound.

15

According to a third aspect of the present invention there is provided a metathesis catalyst which includes a phosphorus containing ligand which is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound.

20

Preferably the metathesis reaction is a homogenous metathesis reaction.

Preferably the ligating phosphorus atom is also bound to a further moiety which is not part of the heterocyclic ring structure.

- Preferably the phosphorus containing ligand comprises a phosphine ligand, preferably a secondary or tertiary phosphine ligand, preferably a tertiary phosphine ligand. The further moiety bound to the ligating phosphorus atom may
- 5 be an atom, and preferably it is H. In an alternative and preferred embodiment of the invention the said moiety may comprise an organyl. The organyl may comprise an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkynyl and optionally it may be substituted. Preferably it comprises alkyl, cycloalkyl or aryl.
- 10 Preferably the heterocyclic organic compound has a single heteroatom in the form of the ligating phosphorus atom.

The heterocyclic organic compound may comprise a bicyclic organic compound. Preferably the heterocyclic organic compound includes no unsaturated carbon to

15 carbon bonds. Preferably the two ring structures have at least 3 shared atoms. Preferably the two ring structures do not have more than 12 ring atoms, preferably they have nine ring atoms.

In a preferred embodiment of the invention the phosphine ligand comprises a

20 bicyclic tertiary phosphine having a ligating phosphorus atom which is preferably bound to two first atoms (preferably carbon atoms) in the ring structure with each of said first atoms being bound to two other second atoms (preferably carbon atoms) in the ring structure. Preferably both the second atoms are carbon atoms.

It will be appreciated that in this embodiment each first atom is bound to three ring atoms.

In a preferred embodiment of the invention the heterocyclic organic compound

5 comprises a phosphacycloalkane, preferably a phosphabicycloalkane, preferably a phosphabicyclononane, each of which optionally may be substituted.

Preferably it comprises a monophosphacycloalkane, preferably a monophosphabicycloalkane, preferably a monophosphabicyclononane.


Preferably the compound comprises a tertiary phosphine.

10

In a preferred embodiment of the invention, the phosphabicyclononane is a 9-phosphabicyclo[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof:



..... (2a)



..... (2b)

20

wherein R₁ is H or an organyl. Preferably R₁ is an optionally substituted alkyl, or optionally substituted aryl, or an optionally substituted cycloalkyl.

5 The phosphabicyclononane may be a compound of formula 2a.

In one embodiment of the invention R₁ is alkyl, preferably -C₂₀H₄₁ also known as eicosyl. In this instance the ligand is known as eicosyl phoban (that is for both compounds of formula 2a and 2b
10 where R₁ is -C₂₀H₄₁).

In one preferred embodiment of the invention R₁ is cyclohexyl. In this instance the ligand is known as cyclohexyl phoban (that is for both compounds of formula 2a and 2b where R₁ is cyclohexyl).


15

The catalyst or metathesis catalyst may comprise a transition metal based catalyst, preferably a group VIII metal based catalyst, preferably a Ru based catalyst. The catalyst may include ligands as defined below.

20

The metathesis reaction may comprise cross metathesis (including self metathesis and ethenolysis), ring-opening metathesis polymerisation or ring-closing metathesis.

According to another aspect of the present invention there is provided a compound of formula 3:



5

.....(3)

wherein L_1 is a neutral electron donor ligand;

L_2 is a phosphorous containing ligand in the form of a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound;

X_1 and X_2 are independently selected from an anionic ligand; and
 R' and R'' are independently selected from H or an organyl.

15

Preferably the compound is a catalyst, preferably a metathesis catalyst, and preferably a homogeneous metathesis catalyst.

Ligand L_1

20

L_1 may be selected from the group consisting of phosphine, sulfonated phosphine, phosphite, phosphinite, phosphonite, arsine, stibine, amine, amide, imine, nitrosyl, carbene and pyridine. In a preferred embodiment of the invention L_1 may be any neutral phosphine ligand or carbene ligand. Preferably L_1 is a

phosphine preferably a phosphine of the formula $\text{PR}^3\text{R}^4\text{R}^5$, wherein R^3 , R^4 and R^5 are each independently aryl, $\text{C}_1 - \text{C}_{10}$ alkyl or cycloalkyl. Preferably L_1 is selected from the group consisting of $-\text{P}(\text{cyclohexyl})_3$; $-\text{P}(\text{cyclopentyl})_3$; $-\text{P}(\text{isopropyl})_3$; and $-\text{P}(\text{phenyl})_3$. Preferably it comprises a neutral phosphine ligand as defined in respect of L_2 . Accordingly L_1 may be the same as L_2 .


In another embodiment of the invention L_1 may be selected from a group of heterocyclic compounds containing substituted or unsubstituted five membered rings which may be saturated or unsaturated and which may include at least two adjacent or non adjacent nitrogen atoms as part of the group. Examples of such ligands are illustrated as formulas 4, 5 and 6:



or



or



15

(4)

(5)

(6)

wherein R'' and R''' may be any group such as H or an organyl, including alkyl, aryl, cycloalkyl, adamantyl or the like, and may be further substituted with functional groups.

Ligand L_2

L_2 is preferably a phosphorus containing ligand as already described above.

25 Namely, the phosphorus containing ligand may comprise a phosphine ligand,

preferably a secondary or tertiary phosphine ligand, preferably a tertiary phosphine ligand. The ligating phosphorus atom may also be bound to a further moiety which is not part of the heterocyclic ring structure. The further moiety bound to the ligating phosphorus atom may be an atom, and preferably it is H. In 5 an alternative and preferred embodiment of the invention the said moiety may comprise an organyl. The organyl may comprise an alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, cycloalkyenyl and optionally it may be substituted. Preferably it comprises alkyl, cycloalkyl or aryl.

10 Preferably the heterocyclic organic compound has a single heteroatom in the form of the ligating phosphorus atom.

The heterocyclic organic compound may comprise a bicyclic organic compound. Preferably the heterocyclic organic compound includes no unsaturated carbon to 15 carbon bonds. Preferably the two ring structures have at least 3 shared atoms. Preferably the two ring structures do not have more than 12 ring atoms, preferably they have nine ring atoms.

In a preferred embodiment of the invention the phosphine ligand comprises a 20 bicyclic tertiary phosphine having a ligating phosphorus atom which is preferably bound to two first atoms (preferably carbon atoms) in the ring structure with each of said first atoms being bound to two other second atoms (preferably carbon atoms) in the ring structure. Preferably both the second atoms are

carbon atoms. It will be appreciated that in this embodiment each first atom is bound to three ring atoms.

In a preferred embodiment of the invention the heterocyclic organic compound


- 5 comprises a phosphacycloalkane, preferably a phosphabicycloalkane, preferably a phosphabicyclononane, each of which optionally may be substituted. Preferably it comprises a monophosphacycloalkane, preferably a monophosphabicycloalkane, preferably a monophosphabicyclononane. Preferably the compound comprises a tertiary phosphine.

10

In a preferred embodiment of the invention, the phosphabicyclononane is a 9-phosphabicyclo-[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof:



..... (2a)



..... (2b)

- 15 20 wherein R₁ is H or an organyl. Preferably R₁ is an organyl, preferably an optionally substituted alkyl, or optionally substituted.

aryl, or an optionally substituted cycloalkyl. The phosphabicyclononane may be a compound of formula 2a.

In one embodiment of the invention the organyl comprises alkyl, preferably $-C_{20}H_{41}$ also known as eicosyl. In this instance the

5 ligand is known as eicosyl phoban (that is for both compounds of formula 2a and 2b where R_1 is $-C_{20}H_{41}$).

In one preferred embodiment of the invention R_1 is cyclohexyl. In this instance the ligand is known as cyclohexyl phoban (that is for

10 both compounds of formula 2a and 2b where R_1 is cyclohexyl.

Ligands X_1 and X_2

X_1 and X_2 may be independently selected from hydrogen; halide; or a compound

15 selected from the group consisting of $C_1 - C_{20}$ alkyl; aryl; $C_1 - C_{20}$ alkoxide; aryloxide; $C_3 - C_{20}$ alkyldiketonate; aryldiketonate; $C_1 - C_{20}$ carboxylate; arylsulfonate; $C_1 - C_{20}$ alkylsulfonate; $C_1 - C_{20}$ alkylthiol; aryl thiol; $C_1 - C_{20}$ alkylsulfonyl; and $C_1 - C_{20}$ alkylsulfinyl, the compound being optionally substituted with one or more other moieties selected from the group consisting of

20 $C_1 - C_{10}$ alkyl; $C_1 - C_{10}$ alkoxy; aryl and halide. Preferably X_1 and X_2 are each independently selected from the group consisting of halide; CF_3CO_2 ; CH_3CO_2 ; CFH_2CO_2 ; $(CH_3)_3CO$; $(CF_3)_2(CH_3)CO$; $(CF_3)(CH_3)_2CO$; PhO; MeO; EtO; tosylate; mesylate; and trifluoromethanesulfonate. Preferably X_1 and X_2 are each independently selected from halide. Preferably X_1 and X_2 are each chloride.

Substituents R' and R"


R' and R" are each independently selected from hydrogen or an organyl selected
5 from the group consisting of C₁-C₂₀ alkyl; C₂-C₂₀ alkenyl; C₂-C₂₀ alkynyl; aryl; C₁-C₂₀ carboxylate; C₁-C₂₀ alkoxy; C₂-C₂₀ alkenyloxy; C₂-C₂₀ alkynyoxy; aryloxy; C₂-C₂₀ alkoxycarbonyl; C₁-C₂₀ alkylthiol; aryl thiol; C₁-C₂₀ alkylsulfonyl and C₁-C₂₀ alkylsulfinyl, the organyl being optionally substituted with one or more moieties
10 preferably selected from the group consisting of C₁-C₁₀ alkyl; C₁-C₁₀ alkoxy; aryl; and a functional group selected from the group consisting of hydroxyl; thiol; thioether; ketone; aldehyde; ester; ether; amine; imine; amide; nitro; carboxylic acid; disulfide; carbonate; isocyanate; carbodiimide; carboalkoxy; carbamate; and halogen. Preferably R' is hydrogen and R" is phenyl or vinyl, optionally substituted with one or more moieties selected from the group consisting of C₁-C₅
15 alkyl; C₁-C₅ alkoxy; phenyl; and a functional group selected from the group consisting of hydroxyl; thiol; thioether; ketone; aldehyde; ester; ether; amine; imine; amide; nitro; carboxylic acid; disulfide; carbonate; isocyanate; carbodiimide; carboalkoxy; carbamate; and halogen. Preferably R' is H and R" is phenyl or -C=C(CH₃)₂.

20

In some cases some of the ligands X₁, X₂, L₁, L₂, R' and R" may be linked to each other, for example:

25

L₁ to X₁ for example to form a bidentate Schiff base ligand such as:




5

wherein L_2 is as defined above.

In a preferred embodiment of the invention, the catalyst may be of the structure of formula 7, wherein L_2 is the same or different and is as defined above.

10 Preferably L_2 are the same and preferably L_2 is a phosphabicyclononane ligand.

In a preferred embodiment L_2 may be a 9-phosphabicyclononane ligand of formula 2a or 2b. Preferably L_2 is cyclohexyl phoban.




.....(7)

15

In another preferred embodiment of the invention, the catalyst may be of the structure of formula 8, wherein L_2 is the same or different and is as defined above. Preferably L_2 are the same and preferably L_2 is a phosphabicyclononane ligand. In a preferred embodiment L_2 may be a 9-phosphabicyclononane ligand

20 of formula 2a or 2b. Preferably L_2 is cyclohexyl phoban.



.....(8)

According to another aspect of the invention there is provided the use of a
5 catalyst of formula 3 above in a metathesis reaction, preferably a homogeneous
metathesis reaction.

The reaction is preferably a homogeneous metathesis reaction of preferably at
least one olefinic compound and the reaction conditions for the metathesis
10 reaction wherein the catalyst of formula 3 is used may be in accordance to
conditions which are well known to a person skilled in the art of metathesis
reactions.

The at least one olefinic compound may comprise an olefin with one or more
15 double bonds or a compound which includes an olefinic moiety with one or more
double bonds. Preferably the olefinic compound has a single double bond in the
case of a cross-metathesis reaction. Preferably the olefinic compound has two
double bonds in the case of a ring-closing metathesis reaction. Preferably the
olefinic compound is a cyclic olefin in the case of a ring-opening metathesis
20 polymerisation reaction.

According to a further aspect of the invention there is provided a metathesis product produced by a metathesis reaction using a catalyst substantially as described hereinabove.

- 5 The metathesis catalyst may be a Grubbs catalyst of formula 3 hereinbefore, preferably a homogeneous metathesis catalyst.

According to yet a further aspect of the invention there is provided a catalysed metathesis reaction wherein at least one olefinic compound is subjected to
10 metathesis in the presence of a catalyst of the type described hereinbefore. Preferably the metathesis reaction is a homogeneous metathesis reaction.

According to yet a further aspect of the invention there is provided a process for a ring closing metathesis reaction in the presence of a catalyst of the type
15 described hereinbefore. According to yet a further aspect of the invention there is provided a process for a ring opening metathesis polymerization reaction in the presence of a catalyst of the type described hereinbefore. According to yet a further aspect of the invention there is provided a process for a cross or self metathesis reaction in the presence of a catalyst of the type described
20 hereinbefore. The cross metathesis reaction may specifically be an ethenolysis reaction (where one of the two olefinic compounds is ethylene). The metathesis reactions preferably comprise homogeneous metathesis reactions.

- The process may further be characterised therein that the catalyst may be formed *in situ*. The process may then include the steps of adding together sufficient quantities of a source of ruthenium which may be an inorganic salt of ruthenium e.g. RuCl₃.xH₂O, a source of ligand in the form of L₂ described above,
- 5 a precursor which would form the carbene structure on the central Ru atom for example an alkyne like butynedioldiacetate and a requisite starting material for the metathesis reaction.
- 10 Without thereby limiting the scope of the invention it will now be further described with reference to the following examples.

Example 1

15 IN SITU FORMED CATALYSIS

This example is in respect of the homogeneous metathesis of 1-octene to form 7-tetradecene using an *in situ* formed catalyst system with a ruthenium concentration of 100ppm. The comparison is between the phosphine ligands

20 eicosyl phoban (EP) and PCy₃ as ligands in an *in situ* formed metathesis catalyst.

General experimental procedure:

Reactions were carried out in a 100 ml three-necked flask fitted with a reflux

25 condenser, thermometer and septum. The reflux condenser was connected to a

cooling bath to ensure a constant flow of chilled water through the jacket, thereby preventing loss of octene. The top of the condenser was connected to a cold trap and bubbler in order to monitor liquid losses and gas emissions. The thermometer was positioned below the level of the reaction solution to ensure 5 correct temperature monitoring. The reaction flask was purged with argon to ensure removal of oxygen. The reagents [EP or PCy₃, RuCl₃.xH₂O and 1,4-butynedioldiacetate (BDD) and 1-octene)] were added to the flask under inert conditions, then a slow hydrogen sparge (2 bubbles per second) was started and maintained during the reaction. The reaction mixture was heated, with stirring, to 10 the desired temperature. Samples were taken at regular intervals with a syringe through the septum and quenched with a mixture of toluene and two drops of *t*-butylhydroperoxide. Samples were analyzed by GC using a Pona column. Unless otherwise stated, 20 ml of octene was employed in all experiments, and catalyst, solvent and additive amounts were calculated relative to this. 15 Octadecane in an amount of 0.5ml was used as internal standard. The conversion percentages (as molar%) of 1-octene to 7-tetradecene are provided in Figures 1 and 2.

1.1 Comparison of EP and PCy₃ as ligands in the metathesis reaction at 50°C

It is evident from the graph in Figure 1 that EP performs far better than PCy₃ at 50°C, affording higher reaction rates and conversions.


Reaction conditions:

100 ppm Ru

2.5:1 phosphine ligand :ruthenium (molar ratio)

10:1 BDD:Ru (molar ratio)

5 T = 50°C

Figure 11.2 Comparison of EP and PCy₃ as ligands in the metathesis reaction at25 110°C.

It is evident from the graph in Figure 2 that at high temperatures, EP shows similar reaction rates and affords higher yields at lower ligand concentrations (1.5:1 molar ratio for EP versus 2.5:1 molar ratio for PCy₃).

Reaction conditions:


100 ppm Ru

2.5:1 and 1.5:1 phosphine ligand :ruthenium (molar ratio)

10:1 BDD:Ru (molar ratio)

5 T = 110°C

Figure 2



At higher temperatures with a 2:5 molar ratio of phosphine ligand to ruthenium, PCy₃ affords improved reaction rates compared to the corresponding EP reaction 30 which is slower. However EP catalyst stability is sustained over a far longer period, and the end of run conversions are the same for both. This suggests that EP coordinates more strongly to the metal center, thereby giving added catalyst stability but slowing reaction rates as phosphine dissociation is hindered.

[According to the generally accepted reaction mechanism, phosphine dissociation is required before metathesis can proceed].

In order to further explore this, less ligand was added (EP or PCy₃: Ru molar ratio 5 of 1.5:1). In the case of PCy₃ [not shown] lower ligand concentrations led to poorer yields of the desired metathesis product, presumably due to lower catalyst stabilities. However in the case of EP, lower ligand concentrations afforded improved reaction rates and yields. Thus at 110°C, only 1.5 equivalents of EP are required to get similar reaction rates and improved yields of desired product 10 relative to those obtained with 2.5 equivalents of PCy₃. The reduced amount of ligand required allows a tremendous reduction in process costs.

Example 2

15 PREFORMED CATALYSTS


Preparation of cyclohexyl phoban is as follows:

A 3-neck round bottomed flask equipped with pressure-equalising dropping 20 funnel was charged with 1,5-cyclooctadiene (de-oxygenated, 5.3 mL, 4.663 g, 4.31×10⁻² mols) and cyclohexylphosphine (6.0 mL, 5.250 g, 4.52×10⁻² mols) and heated to 105°C. A toluene (d/d/d, 20 ml) solution of VAZO® (VAZO® = 1,1'-Azobis(cyclohexanecarbonitrile; 3 g) was then added dropwise to the vigorously stirred solution over 2 hours and the solution heated at 105°C for a further 21

hours. At this point a further 0.5 g of VAZO® (as a solid) was added to the reaction mixture and heating continued for a further 8 hours. After this time the volatiles were removed *in vacuo* to leave a viscous, pale yellow, oil.

- 5 The oil was subjected to a short-path distillation (fraction distilling at >96°C collected) to leave a white, waxy solid (analysis showed this to be contaminated with VAZO decomposition products). This solid was then subjected to a Kugelrohr distillation and the fraction distilling at ~110°C recovered (4.570 g, 47 % as a white, waxy solid). The ligand was isolated as a 3:1 mixture of [3.3.1] and
- 10 [4.2.1] isomers; ^{31}P NMR (C_6D_6): 13.6, -25.3 ppm. That is cyclohexyl phoban formed, that is the compound of formula 2a and 2b wherein R_1 is cyclohexyl.


- The catalysts were prepared according to the following reaction scheme. Complex B was prepared using the known literature method of Fogg et al [D. Amoroso, J. L. Snelgrove, J. C. Conrad, S. D. Drouin, G. P. A. Yap and D. E. Fogg, *Adv. Synth. Catal.*, 2002, 344, 757].



- 20 A specific procedure for preparation of the compound of formula 8 wherein L_2 is cyclohexyl phoban from complex B via this route is as follows:

A solution of cyclohexyl phoban (0.65 mmol) in CH₂Cl₂ (10 ml) was added dropwise to complex (B) (0.26 mmol) in CH₂Cl₂ (10 ml) and stirred overnight at room temperature. The solution turned from dark brown to purple. The solvent was removed *in vacuo* followed by the addition of petroleum ether (20 ml). The 5 solution was cooled to -15 °C to precipitate the product of formula 8 wherein L₂ is cyclohexyl phoban as a purple solid (0.14 mmol, 55% yield). ³¹P NMR (121.4 MHz, CD₂Cl₂) δ 22 (very broad); ¹H NMR (300 MHz, CD₂Cl₂) δ 19.6 (d, Ru=CH, 1H, ³J_{HH} = 11.52 Hz), 8.2 (d, Ru=CHCH, 1H, ³J_{HH} = 11.7 Hz). ¹³C NMR (75.4 MHz, CD₂Cl₂) δ 284 (m, Ru=C). The X-ray crystal structure for this complex is 10 shown below in Figure 3. Selected bond length and angle data is shown in the Table 1.

Figure 3



5


10

15

Table 1. Bond lengths [\AA] and angles [$^\circ$] for the compound of Figure 3

Bond	Lengths and Angles
Ru(1)-C(1)	1.795(7)
Ru(1)-P(11)	2.3834(16)
Ru(1)-P(31)	2.3842(17)
Ru(1)-Cl(1)	2.3983(17)
Ru(1)-Cl(2)	2.4025(16)
C(1)-Ru(1)-P(11)	99.6(2)
C(1)-Ru(1)-P(31)	98.2(2)
P(11)-Ru(1)-P(31)	162.23(6)
C(1)-Ru(1)-Cl(1)	93.0(3)
P(11)-Ru(1)-Cl(1)	90.24(6)
P(31)-Ru(1)-Cl(1)	88.36(6)
C(1)-Ru(1)-Cl(2)	93.3(3)
P(11)-Ru(1)-Cl(2)	88.94(6)
P(31)-Ru(1)-Cl(2)	90.50(6)
Cl(1)-Ru(1)-Cl(2)	173.66(7)

- 5 One possible preparation of such catalysts where the alkylidene is specifically a benzylidene group (that is a compound of (formula 7), involves the displacement of tricyclohexyl phosphine (PCy_3) from the standard first generation Grubbs catalyst (1a). A specific example for the preparation of the benzylidene complex of formula 7 (wherein L_2 is cyclohexyl phoban) is as follows:



10

.....(7)

To a suspension of the Grubbs catalyst of formula 1a (10 mmol) and cyclohexyl phoban (40 mmol) was added degassed DCM (15 ml). After stirring at room temperature for 16 h, the solvent was removed, and degassed pentane was added to the residue. The mixture was sonicated for 1 min, and the solid filtered.

- 5 To the solid was added degassed cold MeOH. The suspension was sonicated again for 1 min and filtered. The complex of formula 7 wherein L₂ is cyclohexyl phoban was isolated as a purple solid (5.8 mmol, 58%). ¹H NMR (300 MHz, d⁸ Toluene): 20.2 ppm (s, 1H, Ru=CH), 9.7 ppm (bs, 1H, o-H of C₆H₅), 7.5 ppm (bs, 1H, o-H of C₆H₅), 7.1 ppm (t, ³J_{HH} = 7.6 Hz, p-H of C₆H₅), 2.6 ppm (4H, P-C-H of Phoban), 2.20-0.70 ppm (m, 46H). ³¹P NMR (121 MHz, d⁸ Toluene): 24 ppm (bs). Mass Spec: (TOF MS ES+); 733.728 (M + Na)⁺, 710.74 (M⁺).
- 10

CATALYSIS EXPERIMENTS WITH PREFORMED CATALYSTS

- 15 The performance of the novel catalysts was compared with the standard first generation Grubbs catalyst (**1a**) and in some cases with the standard second generation catalyst (**1b**) in homogeneous metathesis reactions.


2.1 RING CLOSING METATHESIS WITH COMPOUND 7 (L₂ = Cyclohexyl Phoban)

Reactions were carried out in a 250 ml three-necked flask fitted with a reflux condenser, thermometer and septum. A needle inserted through the septum and connected to a gas supply via a needle valve was used to

ensure a slow and steady stream of argon through the reaction solution.

Dry, degassed toluene (80 ml) was added, followed by diethyldiallylmalonate (4g, 16.8 mmol) and the reaction was heated at 50°C. The catalyst of formula 7 wherein L₂ is cyclohexyl phoban (0.01 mmol) was weighed into a custom-made aluminum weighing tray and added to the reaction mixture. Samples were taken at regular intervals via syringe through the septum. Samples were analysed by GC with a Pona column using an FID. Results are shown in Figure 4 below.

10 Figure 4



It is evident that the catalyst of formula 7 (L₂ = cyclohexyl phoban) performs ring-closing metathesis of diethyldiallylmalonate to form cyclopent-3-ene-1,1-

15 dicarboxylic acid diethyl ester (at a substrate to catalyst molar ratio of 1680/1, 50 deg, 0.01 M in toluene) significantly faster than the catalyst of formula 1a and


compares favourably to results obtained with the much more expensive catalyst of formula 1b.

2.2 RING OPENING METATHESIS POLYMERIZATION WITH COMPOUND

5 7 (L_2 = Cyclohexyl Phoban)

10 Into a glass vial was added 2ml of dry, degassed toluene, followed by decane (900 μ l, internal standard for GC) COD (0.46 g, 4.63 mmol) was added, followed by toluene. A solution of catalyst (0.001838 mmol) in toluene (100 μ l) was added and the reaction was monitored by GC by taking samples at regular intervals. Results are shown Figure 5 below.

Figure 5




It is clear that the catalyst of formula 7 (L_2 =cyclohexyl phoban) catalyses ROMP of 1,5-cyclooctadiene (COD) to form 1,4-polybutadiene faster than the catalyst for formula 1a at a substrate to catalyst molar ratio (S/C) of 2500/1)

5 2.3 CROSS METATHESIS WITH COMPOUND 7 (L_2 = Cyclohexyl Phoban)

2.3.1 1-DECENE METATHESIS, 65°C.

Reactions were carried out in a 250 ml three-necked flask fitted with a
10 reflux condenser, thermometer and septum. A needle inserted through the
septum and connected to a gas supply *via* a needle valve was used to
ensure a slow and steady stream of argon through the reaction solution.
Dry, degassed 1-decene (24 ml) was added, and the reaction was heated
at 65°C. The catalyst (0.014 mmol) was weighed into a custom-made
15 aluminum weighing tray and added to the reaction mixture. Samples were
taken at regular intervals *via* syringe through the septum. Samples were
analysed by GC using a Pona column. Results are shown in Figure 6
below.

Figure 6



5

Under identical conditions, the catalyst of formula 1a showed a poor performance, for the 1-decene metathesis to 9-octadecene while the catalyst of formula 1b showed lower final yields of the desired product due to extensive formation of side products. The catalyst of formula 7 (L₂=cyclohexylphoban) gave the highest yield of desired product.

10

2.3.2 1-OCTENE METATHESIS, 50 DEGREES.

15

Reactions were carried out in a 100 ml three-necked flask fitted with a reflux condenser, thermometer and septum. A needle inserted through the septum and connected to a gas supply via a needle valve was used to ensure a slow and steady stream of argon through the reaction solution.

Dry, degassed 1-octene (20 ml) was added, and the reaction was heated at 50°C. The catalyst (0.014 mmol) was weighed into a custom-made aluminum weighing tray and added to the reaction mixture. Samples were taken at regular intervals *via* syringe through the septum. Samples were 5 analysed by GC using a Pona column. Results are shown in the Table 2 below.

Table 2

Time (min)	Product Yield (molar %)	
	Catalyst 1a	Catalyst 7 (L_2 =cyclohexyl phoban)
120	34%	57%
360	34%	84%

10

Complex 7 (L_2 =cyclohexylphoban) efficiently catalyses the self-metathesis of 1-octene to 7-tetradecene, affording significantly higher yields under the same conditions as 1a. Under the reaction conditions, little visible 15 decomposition is observed, and conversions are significantly higher than those achievable with commercial Grubbs 1st generation catalyst of formula 1a. It is evident that catalyst 1a decomposes within the first two hours of reaction, as no further product formation is observed, while complex 7 (L_2 =cyclohexyl phoban) shows activity over at least 6 hours. 20 Thus complex 7 (L_2 =cyclohexyl phoban) has a superior catalyst lifetime.

2.3.3 ETHENOLYSIS OF 2-OCTENE

A 50ml Parr autoclave was fitted with a 50 ml addition vessel connected via a needle valve to the autoclave diptube. The autoclave was sealed and

5 thoroughly flushed with ethylene. 2-Octene (16.5ml) was introduced to the addition vessel via syringe. It was then introduced to the autoclave by applying 10 bar of ethylene pressure to the addition vessel and opening the needle valve on the diptube. Stirring (1000rpm) was started immediately, and the reactor contents were heated to 45°C. The catalyst
10 (0.018 mmol) was dissolved in the octane (8.5ml), and when the reactor contents were at the desired temperature, the catalyst solution was introduced to the autoclave by applying 15 bar of ethylene pressure to the addition vessel and opening the needle valve on the diptube. Once the reactor pressure had stabilised, the needle valve was closed and the
15 reaction was stirred at 45°C for 2 hours. Samples were taken at intervals and monitored by GC using a Pona column. Results are shown in Table 3 below.

Table 3

Time (min)	2-octene conversion (molar%)	
	Catalyst 1a	Catalyst 7 L ₂ =cyclohexylphoban)
20	17%	27%
40	17%	38%
120	18%	45%

It is evident that complex 7 (L₂=cyclohexylphoban) affords faster reaction rates and higher conversions than catalyst 1a for the reaction of 2-octene and ethylene to form 1-heptene. Catalyst activity is also sustained over a longer period with complex 7 (L₂=cyclohexyl phoban).

2.3.4 CROSS METATHESIS OF SASOL 1-HEPTENE FEED

10

Fischer-Tropsch-derived olefins contain a multitude of impurities which have a deleterious effect on many homogeneous catalysts. A Fischer-Tropsch (FT) derived C₇ feed with the following composition was employed (percentages expressed as molar%):

15

Linear 1-alkene	86%
Linear internal alkene	1-1.5%
Branched alkene (incl. internal)	5-7%
Cyclic alkene	1-2%
Diene	1%

20

Oxygenate	<100ppm
Paraffins, aromatics & other	5-7%

Reactions were carried out in a 100 ml three-necked flask fitted with a reflux condenser, thermometer and septum. A needle inserted through the septum and connected to a gas supply via a needle valve was used to ensure a slow and steady stream of argon through the reaction solution. Dry, degassed 1-heptene feed (20 ml) was added, and the reaction was heated at 50°C. The catalyst (0.014 mmol) was then added as a solid to the preheated reaction mixture. Samples were taken at intervals via syringe through the septum. Samples were analysed by GC using a Pona column. Results are shown in Table 4 below.

Table 4

15

Time (min)	1-heptene conversion (molar%)	
	Catalyst 1a	Catalyst 7 (L_2 =cyclohexyl phoban)
20	19%	39%
60	19%	52%
360	19%	70%

It is evident from these results that complex 7(L_2 =cyclohexyl phoban) affords far superior results to catalyst 1a for the metathesis of a Fischer Tropsch derived 1-heptene feed to form 6-dodecene . It

is also clear that catalyst 1a is poisoned very quickly by trace impurities, as it shows no further conversion of substrate after 20 minutes, and does not reach the conversion obtained with pure 1-octene feed (34%). In comparison, complex 7 (L_2 =cyclohexylphoban) affords much higher conversions of substrate, and catalyst activity is maintained over a longer period. The catalyst therefore shows a greater tolerance to feed impurities.

5

2.4 CROSS METATHESIS OF 1-OCTENE WITH COMPLEX 8 (L_2 =Cyclohexyl Phoban)

10

15

20

Reactions were carried out in a 250 ml three-necked flask fitted with a reflux condenser, thermometer and septum. A needle inserted through the septum and connected to a gas supply via a needle valve was used to ensure a slow and steady stream of argon through the reaction solution. Dry, degassed 1-octene (20 ml) was added, and the reaction was heated at 50°C. The catalyst (0.014 mmol) was weighed into a custom-made aluminum weighing tray and added to the reaction mixture. Samples were taken at regular intervals via syringe through the septum. Samples were analysed by GC using a Pona column. Results are shown in Table 5 below.

Table 5

Product Yield (molar%)		
Time (min)	Catalyst 1a	Catalyst 8 (L_2 =cyclohexyl phoban)
120	34%	44%
360	35%	82%

It is evident from these results that complex 8 (L_2 = cyclohexyl phoban) affords

5 superior results to catalyst 1a for the metathesis of 1-octene to 7-tetradecene.

From the above examples it can be seen that catalysts including ligands according to the present invention and catalysts according to the present invention may have improved performance over the prior art catalysts in at least

10 one of the following aspects:

- i) higher reaction rates;
- ii) higher conversions;
- iii) improved catalyst stability;
- iv) improved rates/yields at lower ligand concentrations; and
- 15 v) higher yields of desired products.

It will be appreciated that many variations in detail are possible without thereby departing from the spirit and scope of the invention.

CLAIMS

5

1. The use of a phosphorus containing ligand as a ligand for a metathesis catalyst in a catalysed metathesis reaction wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the

10 heterocyclic organic compound.

2. The use of a phosphorus containing ligand in the preparation of a catalyst containing the ligand, which catalyst is for use in a metathesis reaction, wherein the phosphorus containing ligand is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound.

15

3. The use of either one of claims 1 or 2 wherein the metathesis reaction is a homogenous metathesis reaction.

20


4. The use of any one of the preceding claims wherein the phosphorus containing ligand comprises a phosphine ligand.

25


5. The use of claim 4 wherein the ligating phosphorus atom is also bound to a further moiety which is an organyl and which is not part of the heterocyclic ring structure.

6. The use of any one of claims 1 to 5 wherein the heterocyclic organic compound comprises a bicyclic organic compound.

7. The use of any one of claims 1 to 4 wherein the phosphorus containing ligand is a 9-phosphabicyclo[3.3.1]nonane of formula 2a or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof:



..... (2a)



..... (2b)

wherein R₁ is H or an organyl.

15

8. The use of claim 7 wherein R₁ is -C₂₀H₄₁.

9. The use of claim 7 wherein R₁ is cyclohexyl.

20 10. The use of any one of the preceding claims wherein the metathesis reaction is a reaction selected from the group


consisting of cross metathesis, ring-opening metathesis polymerisation and ring-closing metathesis.

11. A metathesis catalyst which includes a phosphorus containing ligand which

5 is a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound.

12. A compound of formula 3:

10



.....(3)

wherein

15 L₁ is a neutral electron donor ligand;

L₂ is a phosphorous containing ligand in the form of a heterocyclic organic compound with a ligating phosphorus atom as an atom in the heterocyclic ring structure of the heterocyclic organic compound;

20 X₁ and X₂ are independently selected from an anionic ligand; and

R' and R'' are independently selected from H and an organyl.


13. The compound of claim 12 which is a homogeneous metathesis catalyst.

14. The compound of either one of claims 12 or 13 wherein L₁ is the same as L₂.

15. The compound of any one of claims 12 to 14 wherein the phosphorus containing ligand of L₂ comprises a phosphine ligand.

16. The compound of claim 15 wherein L₂ is a 9-phosphabicyclo[3.3.1]nonane, of formula 2a, or a 9-phosphabicyclo[4.2.1] nonane of formula 2b or mixtures thereof:

10



..... (2a)



..... (2b)

15

wherein R₁ is H or an organyl.


17. The compound of claim 16 wherein R₁ is -C₂₀H₄₁.

20

18. The compound of claim 16 wherein R₁ is cyclohexyl.


19. The compound of any one of claims 12 to 18 wherein X_1 and X_2 are each independently selected from halide.

20. The compound of claim 12 which is a compound of formula 7:



wherein L₂ is the same or different and is as defined in claim 12.

10 21. The compound of claim 12 which is a compound of formula 8



15 12. wherein L₂ is the same or different and is as defined in claim

22. The compound of either one of claims 20 or 21 wherein L₂ is as defined in claim 16.

23. The use of a compound of any one of claims 12 to 21 in a metathesis reaction.

24. The use of claim 23 wherein the metathesis reaction is a homogeneous
5 metathesis reaction selected from the group consisting of cross metathesis ring-opening metathesis polymerisation and ring-closing metathesis.

25. A catalysed metathesis reaction wherein at least one olefinic
10 compound is subjected to metathesis in the presence of a compound of claim 12.

26. The reaction of claim 25 wherein the compound of claim 12 is formed *in situ*.

15

27. A metathesis product formed by the reaction of either one of claims 25 or 26.

20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/ZA 03/00087A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C6/04 C08G61/08 B01J31/24 C07F15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07C C08G B01J C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FÜRSTNER A: "Olefin metathesis and beyond" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 39, 2000, pages 3012-3043,1, XP002957487 ISSN: 0570-0833 cited in the application the whole document ---- -/-	1-27

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

29 October 2003

Date of mailing of the international search report

06/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/ZA 2008/00087

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHOLL M ET AL: "Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands" ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 1, no. 6, 1999, pages 953-956, XP000984756 ISSN: 1523-7060 the whole document ---	1-27
A	TRNKA T. M. ET AL.: "The development of L ₂ X ₂ Ru=CHR olefin metathesis catalysts: An organometallic success story" ACCOUNTS OF CHEMICAL RESEARCH., vol. 34, no. 1, 2001, pages 18-29, XP002951799 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0001-4842 cited in the application the whole document ---	1-27
A	WO 00 58322 A (CALIFOENIA INSTITUTE OF TECHNOLOGY) 5 October 2000 (2000-10-05) the whole document ---	1-27
A	GB 1 109 787 A (SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ N.V.) 18 April 1968 (1968-04-18) the whole document ---	1-27
A	WO 02 14248 A (SASOL TECHNOLOGY) 21 February 2002 (2002-02-21) the whole document -----	1-27

INTERNATIONAL SEARCH REPORT

Internal ref. No.
PCT/ZA2003/00087

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0058322	A 05-10-2000		AU 4189300 A EP 1180107 A1 JP 2002540213 T WO 0058322 A1 US 6426419 B1 US 2002013473 A1	16-10-2000 20-02-2002 26-11-2002 05-10-2000 30-07-2002 31-01-2002
GB 1109787	A 18-04-1968		US 3400163 A BE 678614 A DE 1543471 A1 DE 1667286 A1 FR 1472711 A NL 6604094 A ,B NL 7312880 A ,B, SE 356692 B SE 345254 B US 3420898 A US 3440291 A US 3496203 A US 3496204 A US 3501515 A US 3502730 A	03-09-1968 29-09-1966 21-08-1969 19-05-1971 10-03-1967 30-09-1966 26-11-1973 04-06-1973 23-05-1972 07-01-1969 22-04-1969 17-02-1970 17-02-1970 17-03-1970 24-03-1970
WO 0214248	A 21-02-2002		AU 7662401 A BR 0113209 A CA 2419271 A1 EP 1311344 A2 WO 0214248 A2 US 2003158446 A1	25-02-2002 01-07-2003 21-02-2002 21-05-2003 21-02-2002 21-08-2003

INTERNATIONAL SEARCH REPORT

International Search Report No

PCT/ZA 03/00087

A. CLASSIFICATION OF SUBJECT MATTER			
IPC 7	C07C6/04	C08G61/08	B01J31/24
			C07F15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C08G B01J C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FÜRSTNER A: "Olefin metathesis and beyond" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 39, 2000, pages 3012-3043,1, XP002957487 ISSN: 0570-0833 cited in the application the whole document</p> <p>---</p> <p>-/-</p>	1-27

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the International search report
---	--

29 October 2003

06/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Beslier, L

INTERNATIONAL SEARCH REPORT

Internal
PCT/ZA 03/00087

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SCHOLL M ET AL: "Synthesis and activity of a new generation of ruthenium-based olefin metathesis catalysts coordinated with 1,3-dimesityl-4,5-dihydroimidazol-2-ylidene ligands" ORGANIC LETTERS, AMERICAN CHEMICAL SOCIETY, US, vol. 1, no. 6, 1999, pages 953-956, XP000984756 ISSN: 1523-7060 the whole document ---	1-27
A	TRNKA T. M. ET AL.: "The development of L ₂ X ₂ Ru=CHR olefin metathesis catalysts: An organometallic success story" ACCOUNTS OF CHEMICAL RESEARCH., vol. 34, no. 1, 2001, pages 18-29, XP002951799 AMERICAN CHEMICAL SOCIETY. WASHINGTON., US ISSN: 0001-4842 cited in the application the whole document ---	1-27
A	WO 00 58322 A (CALIFOENIA INSTITUTE OF TECHNOLOGY) 5 October 2000 (2000-10-05) the whole document ---	1-27
A	GB 1 109 787 A (SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ N.V.) 18 April 1968 (1968-04-18) the whole document ---	1-27
A	WO 02 14248 A (SASOL TECHNOLOGY) 21 February 2002 (2002-02-21) the whole document -----	1-27

INTERNATIONAL SEARCH REPORT

Internal
cation No
PCT/ZA 03/00087

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0058322	A 05-10-2000	AU EP JP WO US US	4189300 A 1180107 A1 2002540213 T 0058322 A1 6426419 B1 2002013473 A1	16-10-2000 20-02-2002 26-11-2002 05-10-2000 30-07-2002 31-01-2002
GB 1109787	A 18-04-1968	US BE DE DE FR NL NL SE SE US US US US US US	3400163 A 678614 A 1543471 A1 1667286 A1 1472711 A 6604094 A ,B 7312880 A ,B, 356692 B 345254 B 3420898 A 3440291 A 3496203 A 3496204 A 3501515 A 3502730 A	03-09-1968 29-09-1966 21-08-1969 19-05-1971 10-03-1967 30-09-1966 26-11-1973 04-06-1973 23-05-1972 07-01-1969 22-04-1969 17-02-1970 17-02-1970 17-03-1970 24-03-1970
WO 0214248	A 21-02-2002	AU BR CA EP WO US	7662401 A 0113209 A 2419271 A1 1311344 A2 0214248 A2 2003158446 A1	25-02-2002 01-07-2003 21-02-2002 21-05-2003 21-02-2002 21-08-2003